• Rilpivirine  (tradename Edurant, developed as TMC-278) is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
  • Standard adult dose: 1 x 25 mg tablet, once daily – at the same time each day.
  • Take with a meal. Absorption is reduced by 40% if taken without food. The meal needs to have solid food. A protein shake is not suitable.
  • Side effects: depressive disorders (depressed mood, depression, mood altered, negative thoughts, suicide attempt, suicidal ideation), rash, nausea, liver problems.
  • Other notes: rilpivirine is currently only approved for use in combinations in people starting treatment for the first time (treatment-naive) who have a viral load that is less than 100,000 copies/mL
  • Resistance to rilpivirine is closely linked to less than perfect adherence.
  • Resistance to rilpivirine is likely to result in resistance to other NNRTIs including nevirapine or efavirenz. For this reason it is not recommended to use if you are not adherent.
  • Rilpivirine is included with tenofovir DF and FTC in a fixed dose single pill formulation called Eviplera (or Complera in the US).

Further information

The European patient information and detailed Product Information for rilpivirine are available in PDF format from this link on the European Medicines Agency (EMA) website.

The US label for rilpivirine (Edurant) can be viewed on the US FDA website as a PDF file at this link.

The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.

The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.